Viewing Study NCT00014612



Ignite Creation Date: 2024-05-05 @ 11:22 AM
Last Modification Date: 2024-10-26 @ 9:06 AM
Study NCT ID: NCT00014612
Status: COMPLETED
Last Update Posted: 2013-10-29
First Post: 2001-04-10

Brief Title: Comparison of Complete Axillary Lymph Node Dissection With Axillary Radiation Therapy in Treating Women With Invasive Breast Cancer
Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Organization: European Organisation for Research and Treatment of Cancer - EORTC

Study Overview

Official Title: After Mapping Of The Axilla Radiotherapy Or Surgery
Status: COMPLETED
Status Verified Date: 2013-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: AMAROS
Brief Summary: RATIONALE Radiation therapy uses high-energy x-rays to damage tumor cells and may be a less invasive treatment and cause fewer side effects than complete axillary lymph node dissection It is not yet known which treatment is more effective for invasive breast cancer

PURPOSE Randomized phase III trial to compare the effectiveness of complete axillary lymph node dissection with that of axillary radiation therapy in treating women who have invasive breast cancer
Detailed Description: OBJECTIVES

Compare the regional control of the axilla obtained by complete axillary lymph node dissection vs axillary radiotherapy in sentinel lymph node-positive women with operable invasive breast cancer
Determine whether local and regional axillary control can be obtained without axillary lymph node dissection in sentinel lymph node-negative women
Compare the axillary 5-year recurrence-free survival of these patients treated with these regimens
Compare the morbidity of patients treated with these regimens
Compare the quality of life of these patients treated with these regimens

OUTLINE This is a randomized multicenter study Patients are stratified according to participating center and type of breast surgery conservation vs total mastectomy Patients are randomized to 1 of 2 treatment arms

Patients are given an injection of a tracer and undergo lymphoscintigraphy 2-3 hours later to identify the sentinel lymph node Within 24 hours after lymphoscintigraphy patients undergo wide local excision of the tumor or mastectomy after the sentinel node is removed If no sentinel node is found or metastasis is found in a nonsentinel node patients undergo complete axillary lymph node dissection ALND regardless of randomization Sentinel node-negative patients receive no further treatment Sentinel node-positive patients continue treatment according to randomization

Arm I Within 8 weeks after surgery patients undergo complete ALND
Arm II Within 8 weeks after surgery patients undergo axillary lymph node radiotherapy daily 5 days a week for 5 weeks

Patients in arm I may receive postoperative axillary irradiation if 4 or more nodes are positive and more than 1 axillary level is involved

Quality of life is assessed at baseline and then at 1 2 3 and 5 years

Patients are followed annually for 5 years

PROJECTED ACCRUAL A total of 3485 patients 1394 sentinel node-positive and 2091 sentinel node-negative will be accrued for this study within 3 years

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None